These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 11921436)
21. Rationale for and role of thiazolidinediones in type 2 diabetes mellitus. Lebovitz HE Am J Cardiol; 2002 Sep; 90(5A):34G-41G. PubMed ID: 12231077 [TBL] [Abstract][Full Text] [Related]
22. Troglitazone in type II diabetes mellitus. Sparano N; Seaton TL Pharmacotherapy; 1998; 18(3):539-48. PubMed ID: 9620105 [TBL] [Abstract][Full Text] [Related]
23. [Insulin sensitizer. A new therapy option for type 2 diabetic patients]. Filz HP MMW Fortschr Med; 2000 Sep; 142(38):31-3. PubMed ID: 11050888 [TBL] [Abstract][Full Text] [Related]
24. Insulin resistance and its treatment by thiazolidinediones. Lebovitz HE; Banerji MA Recent Prog Horm Res; 2001; 56():265-94. PubMed ID: 11237217 [TBL] [Abstract][Full Text] [Related]
25. Effects of troglitazone on insulin sensitivity. Henry RR Diabet Med; 1996 Sep; 13(9 Suppl 6):S148-50. PubMed ID: 8894499 [TBL] [Abstract][Full Text] [Related]
27. New diabetes drug targets insulin resistance. Am J Health Syst Pharm; 1997 Mar; 54(6):623, 625. PubMed ID: 9075488 [No Abstract] [Full Text] [Related]
28. Thiazolidinediones in the treatment of managed care patients with type 2 diabetes. Pathak R; Afaq A; Blonde L Am J Manag Care; 2002 Oct; 8(16 Suppl):S483-94. PubMed ID: 12408411 [TBL] [Abstract][Full Text] [Related]
30. New oral therapies for type 2 diabetes. Purnell JQ; Hirsch IB Am Fam Physician; 1997 Nov; 56(7):1835-42. PubMed ID: 9371013 [TBL] [Abstract][Full Text] [Related]
31. [A 75-year-old type 2 diabetes mellitus case responding strikingly troglitazone: possible mechanism of insulin resistance induced by insulin antibody]. Takahashi S; Oida K; Miyamori I Nihon Ronen Igakkai Zasshi; 2000 Apr; 37(4):344-8. PubMed ID: 10917034 [TBL] [Abstract][Full Text] [Related]
32. The emerging role of thiazolidinediones in the treatment of diabetes-mellitus and related disorders. Subramaniam S Clin Exp Hypertens; 1999; 21(1-2):121-36. PubMed ID: 10052648 [TBL] [Abstract][Full Text] [Related]
33. Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes. Sironi AM; Vichi S; Gastaldelli A; Pecori N; Anichini R; Foot E; Seghieri G; Ferrannini E Clin Pharmacol Ther; 1997 Aug; 62(2):194-202. PubMed ID: 9284856 [TBL] [Abstract][Full Text] [Related]
34. Economic assessment of troglitazone as an adjunct to sulfonylurea therapy in the treatment of type 2 diabetes. Caro JJ; Klittich WS; Raggio G; Kavanagh PL; O'Brien JA; Shomphe LA; Flegel KM; Copley-Merriman C; Sigler C Clin Ther; 2000 Jan; 22(1):116-27. PubMed ID: 10688395 [TBL] [Abstract][Full Text] [Related]
35. New therapeutic approaches to reversing insulin resistance. Sonnenberg GE; Kotchen TA Curr Opin Nephrol Hypertens; 1998 Sep; 7(5):551-5. PubMed ID: 9818203 [TBL] [Abstract][Full Text] [Related]
37. Learning to use troglitazone. Riddle MC Diabetes Care; 1998 Sep; 21(9):1389-90. PubMed ID: 9727881 [No Abstract] [Full Text] [Related]
38. New directions in type 2 diabetes mellitus: an update of current oral antidiabetic therapy. Brown DL; Brillon D J Natl Med Assoc; 1999 Jul; 91(7):389-95. PubMed ID: 10643211 [TBL] [Abstract][Full Text] [Related]
39. Long-term cardiovascular effects of insulin sensitizer troglitazone on non-diabetic individuals with insulin resistance: double blind, prospective randomized study. Stakos DA; Schuster DP; Sparks EA; Wooley CF; Osei K; Boudoulas H J Cardiol; 2003 Apr; 41(4):183-90. PubMed ID: 12728539 [TBL] [Abstract][Full Text] [Related]